Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective This study assesses whether the relationship of lipoprotein(a) (Lp(a)) with cardiovascular risk may be modified by concurrent hormone therapy (HT). Background Prior studies indicate that hormone therapy (HT) decreases plasma levels of Lp(a), but few have been powered to assess whether it modifies the relationship of Lp(a) with cardiovascular disease (CVD). Methods Lp(a) at baseline was measured among 27,736 initially healthy women, of whom 12,075 indicated active HT use at the time of blood draw at study initiation, and 15,661 did not. The risk of first-ever major cardiovascular event (nonfatal myocardial infarction, nonfatal cerebrovascular event, coronary revascularization or cardiovascular deaths) over a ten-year period was assessed in Cox-proportional hazard models according to Lp(a) levels and HT status, and adjusted for potential confounding variables. Results As anticipated, Lp(a) values were lower among women taking HT (median 9.4 vs. 11.6 mg/dL, P<0.0001). In women not taking HT, the hazard ratio of future CVD for the highest Lp(a) quintile compared to the lowest was 1.8 (P-trend <0.0001), after adjusting for age, smoking, blood pressure, diabetes, body mass index, total cholesterol, HDL, C-reactive protein and treatment arms of aspirin and Vitamin E. In contrast, among women taking HT, there was little evidence of association with CVD [hazard ratio 1.1, P-trend =0.18; interaction P-value 0.0009 between Lp(a) quintiles and HT on incident CVD]. Conclusion The relationship of high Lp(a) levels with increased CVD is modified by hormone therapy. These data suggest that the predictive utility of Lp(a) is markedly attenuated among women taking HT, and may inform clinicians’ interpretation of Lp(a) values in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Self-citationcDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lee, I.-M., Cook, N. R., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.56 · Cited by 1,137
Self-citationCook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Self-citationCARLSON, L. A., HAMSTEN, A., & ASPLUND, A. (1989) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1989.tb01393.x · Cited by 443
Marcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Cited by
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
F. T. G. O. C. I., Jaeger, B. R., Richter, Y., Nagel, D., Heigl, F., Vogt, A., Roeseler, E., Parhofer, K., Ramlow, W., Koch, M., et al. (2009) · Nature Reviews Cardiology · doi:10.1038/ncpcardio1456 · Cited by 294
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
“Lp(a) can be reduced by niacin therapy and, in women, by estrogen therapy.(204,205) A variety of other compounds can change Lp(a), but none is truly suitable as therapeutic agents.”
BackgroundLipoprotein (a): impact by ethnicity and environmental and medical conditions
Enkhmaa, B., Anuurad, E., & Berglund, L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r051904 · Cited by 260
Metadata
- Authors
- Suk Danik, J., Rifai, N., Buring, J. E., & Ridker, P. M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 52
- Issue
- 2
- Pages
- 124-131
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2158808699
- Cited by
- 108
- References
- 9
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. https://app.cochat.ai/papers/10.1016/j.jacc.2008.04.009
- The paper
- Suk Danik, J., Rifai, N., Buring, J. E., & Ridker, P. M. (2008). Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2008.04.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.